The FDA has approved a new drug called zolbetuximab designed to attack a novel target that’s in a type of stomach cancer.
GSK (NYSE:GSK) reported its RSV vaccine Arexvy elicited a robust immune response in recipients aged 18 to 49 years who were ...
Health NGO, Right to Care, highlights the urgent need for circumcision among boys aged 15 and older in KwaZulu-Natal to ...
Overall rates of treatment emergent adverse events (AEs) were 53% for both Dupixent and placebo. AEs more commonly observed with Dupixent (≥5%) compared to placebo included injection site reactions ...
A new study from Washington University School of Medicine in St. Louis suggests that a type of immunotherapy -; similar to that approved by the Food and Drug Administration (FDA) to treat inflammatory ...
Progress has been made in HIV care. However, that doesn’t mean you don’t need a detailed plan for taking care of an ...
Winnie Byanyima, from UNAIDS: ‘Lenacapavir is more effective than condoms or PrEP in prevention’
The executive director of the organization says gender inequality is one of the most important drivers of new infections, ...
Some people infected with HIV are teeming with virus, but don’t get sick. Their resistive powers probably come from a mix of ...
Cisgender gay and bisexual men, transgender women, and transgender men remain at higher risk for HIV acquisition.
“With low uptake of PrEP among the communities most impacted by HIV, this insurance coverage requirement with zero ...
Public health officials in New York are especially concerned about a resurgence of congenital syphilis, which is passed from ...
The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback